Cell Based Screening

Rapid, high-quality single agent and combination therapy screening

invitro-magnifyglass.png

Our Expertise and Capacity brings Rapid Results Ready for Immediate Transfer into Well-Validated In Vivo models

CrownBio understands the need to improve drug discovery/development processes and shorten decision making timelines to enhance R&D productivity. We work closely with our clients to provide cell based screening with a swift turnaround and high quality data, to save precious resources and time.

Our cell based screening platform is designed to enable better decision-making earlier in the drug development process. Equipped with technology such as the powerful IncuCyte® ZOOM platform for real time, quantitative live cell analysis, or the Acumen eX3 microplate cytometer for multiparameter phenotypic screening, CrownBio provides high quality cell based assay services using high content and high-throughput drug screening technology.

Our Know-How, Your Advantage

Our experienced team of scientists has delivered hundreds of successful projects for many renowned Pharmaceutical and Biotech companies, providing services ranging from target validation, drug mechanism of action, assay development, high-throughput drug screening, indication selection, to biomarker discovery.

CrownBio offers comprehensive cell based platforms and extensive tool sets to determine the biological functions of each target, as well as the consequence of pharmacological intervention to help in making go/no go decisions.

A Comprehensive Range of Functional Assay Services

  • High throughput cytotoxicity screening
  • In vitro drug combination studies
  • 3D clonogenic assays
  • 3D Tumor Growth Assays using PrimePanel™ cell lines
  • Target validation studies
  • Adhesion, migration, and invasion assays
  • Angiogenesis assays
  • Apoptosis studies
  • ADCC and CDC analyses
  • Cell cycle analysis
  • Pharmacodynamics/Pharmacokinetics analysis

Contact us today for free expert advice to support all your cell based screening needs.

Quick Facts

Posters

  • AACR 2015 1038 - Cell-based Screening Identifes Gene Expression Signature Correlated with Sensitivity to PI3KmTOR Dual Inhibitor BEZ235
  • AACR 2014 3440 - Cell-based Screening Identifies Gene Expression Signature Correlated with Sensitivity to MEK Inhibitor Trametinib

Related Services

Blog Posts